TY - JOUR AU - La Vincente, S. F. AU - von Mollendorf, C. AU - Ulziibayar, M. AU - Satzke, C. AU - Dashtseren, L. AU - Fox, K. K. AU - Dunne, E. M. AU - Nguyen, C. D. AU - de Campo, J. AU - de Campo, M. AU - Thomson, H. AU - Surenkhand, G. AU - Demberelsuren, S. AU - Bujinlkham, S. AU - Do, L. A. H. AU - Narangerel, D. AU - Cherian, T. AU - Mungun, T. AU - Mulholland, E. K. PY - 2019 DA - 2019/03/21 TI - Evaluation of a phased pneumococcal conjugate vaccine introduction in Mongolia using enhanced pneumonia surveillance and community carriage surveys: a study protocol for a prospective observational study and lessons learned JO - BMC Public Health SP - 333 VL - 19 IS - 1 AB - Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation. Measuring PCV impact can be complex, particularly to measure impact on one of the most common and significant diseases caused by the pneumococcus, namely pneumonia. Here we outline the protocol developed to evaluate the impact of 13-valent PCV (PCV13) on childhood pneumonia in Mongolia, and a number of lessons learned in implementing the evaluation that may be helpful to other countries seeking to undertake pneumonia surveillance. SN - 1471-2458 UR - https://doi.org/10.1186/s12889-019-6639-y DO - 10.1186/s12889-019-6639-y ID - La Vincente2019 ER -